参芪注射液对重组人血管内皮抑素联合化疗致心脏毒性的保护作用

Protective Effect of Shenqi Injection on Cardiac Toxicity Caused By Recombinant Human Endostatin Combined with Chemotherapy

目的观察参芪注射液对重组人血管内皮抑素(恩度)联合化疗所致心脏毒性的保护作用。方法将48例经病理确诊的Ⅲ、Ⅳ期恶性肿瘤患者,分成治疗组(在恩度联合化疗基础上加参芪注射液)和对照组(恩度联合化疗),观察两组治疗前后左室射血分数(LVEF)、心电图(EKG)、心肌酶谱、血浆肌钙蛋白Ⅰ(troponinⅠ)的变化和心血管不良反应。结果对照组LVEF下降而治疗组LVEF升高,组间差异有显著性(P<0.05);对照组心电图异常发生率(41.66%)有高于治疗组(25.00%)的趋势(P>0.05);两组心肌酶升高及心血管不良反应相关症状比较无显著性差异(P>0.05)。治疗组的生活质量提高(P<0.05);两组近期疗效无显著性差异(P>0.05)。结论参芪注射液对恩度联合化疗的心脏不良反应有一定保护作用,主要表现为维持左室射血功能,同时不影响疗效。

Objective To observe the protective effect of Shenqi Injection on the cardiac toxicity caused by the recombinant human endostatin（Endosta）r combined with chemotherapy.Methods A prospective non-randomized case-controlled trial was carried out in 48 patients who had the final diagnosis of malignant tumor of Ⅲ or Ⅳ stage through histopathological examination.The patients were divided into two groups according to the use of Shenqi Injection（research group or Group A）or no（tcontrol group or Group B）during the treatment with endostar combined chemotherapy.Left ventricular ejection fraction（LVEF）,electrocardiogram（ECG）,myocardial enzymogram,plasma troponin Ⅰ（troponin Ⅰ）,cardiovascular adverse reaction were evaluated before and after the treatment.Results LVEF was decreased in Group B while increased in Group A,the difference being significant（P 0.05）.The incidence of abnormal electrocardiogram was 41.66 % in Group B and 25.00% in Group A,the difference being insignifican（tP 0.05）.The differences of the increase of myocardial enzymogram and cardiovascular adverse reactions were not significant between two groups（P 0.05）.QOL was improved in Group A（P 0.05）,while the short-term therapeutic effect in Group A was similar to that in Group B（P 0.05）.Conclusion Shenqi Injection exerts certain protective effect on the cardiac adverse reaction caused by endostatin combined chemotherapy,which is mainly shown as maintaining the left ventricular ejection function while having no influence on antitumor effect.